首页> 外文OA文献 >Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

【2h】

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

机译：用于靶向PD-1 / PD-L1轴的临床终体基质与多发性骨髓瘤和其他CD38阳性恶性肿瘤中的CD38抗体组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Christie P. M. Verkleij; Amy Jhatakia; Marloes E. C. Broekmans; Kristine A. Frerichs; Sonja Zweegman; Tuna Mutis; Natalie A. Bezman; Niels W. C. J. van de Donk;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials [J] . Ye Wu, Wu Xia, Liu Xiaoyan, BMC Cancer . 2021,第1期

机译：靶向CD38，SLAMF7和PD-1 / PD-L1与硼齐佐米/免疫调节器的单克隆抗体的比较与硼替佐米/免疫调节剂加上甲基塞塞酮/泼尼松治疗多发性骨髓瘤：随机对照试验的间接比较荟萃分析
2. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. [J] . Benson DM Jr, Bakan CE, Mishra A, Blood: The Journal of the American Society of Hematology . 2010,第13期

机译：PD-1 / PD-L1轴调节自然杀伤细胞对多发性骨髓瘤的作用：CT-011（一种新型的单克隆抗PD-1抗体）的治疗靶标。
3. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? [J] . Rosenblatt Jacalyn, Avigan David Blood: The Journal of the American Society of Hematology . 2017,第3期

机译：靶向多个骨髓瘤中的PD-1 / PD-L1轴：梦想或现实？
4. Molecular dynamics of the immune checkpoint Programmed Cell Death Protein I, PD-1: Conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [C] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner IEEE International Conference on Bioinformatics and Biomedicine . 2019

机译：免疫检查点的分子动力学程序性细胞死亡蛋白I，PD-1：配体PD-L1与单克隆抗体nivolumab结合后BC环的构象变化
5. Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation [D] . Miller, Kevin Charles. 2020

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
6. Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies [O] . Christie P. M. Verkleij, Amy Jhatakia, Marloes E. C. Broekmans, 2020

机译：用于靶向PD-1 / PD-L1轴的临床终体基质与多发性骨髓瘤和其他CD38阳性恶性肿瘤中的CD38抗体组合
7. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1 [O] . Andriani C. Patera, Anne M. Drewry, Katherine Chang, 2016

机译：前线科学：败血症患者免疫功能的缺陷与PD-1或PD-L1表达相关，可以通过靶向PD-1或PD-L1的抗体恢复

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

著录项

引文网络

相似文献

相关主题

期刊订阅